Triple Incretin vs Oral Peptide — Metabolic Deal Terms Comparison
Market Analysis
In metabolic, Triple Incretin and Oral Peptide represent two of the most actively transacted modalities. At Phase 2, Triple Incretin deals carry a median total deal value of $5.6B with $1.2B upfront, compared to $6.7B total value and $1.4B upfront for Oral Peptide. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Triple Incretin development milestones average $803M versus $954M for Oral Peptide. Commercial milestones are $2.7B for Triple Incretin and $3.2B for Oral Peptide. Royalty rates range from 17.2%-30% for Triple Incretin and 18.1%-30% for Oral Peptide.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Triple Incretin and Oral Peptide deal terms compare in metabolic?
Which modality commands higher royalty rates: Triple Incretin or Oral Peptide?
How do milestone structures differ between Triple Incretin and Oral Peptide?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.